HealthDay News — Microneedle array (MNA) supply of trimeric coronavirus spike (S) protein subunit vaccines appears promising for immunization towards extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an infection, in line with analysis printed on-line April 2 in EBioMedicine.
Noting that coronavirus S protein is taken into account a key goal for vaccines for prevention of coronavirus an infection, Eun Kim, from the University of Pittsburgh School of Medicine, and colleagues report on the event of MNA-delivered Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) vaccines and their preclinical immunogenicity. Codon-optimized MERS-S1 subunit vaccines fused with a foldon trimerization area have been generated to imitate the native viral construction. Immune stimulants have been engineered into this trimeric design in variant constructs. By evaluating virus-specific immunoglobulin G antibodies within the serum of vaccinated mice and utilizing virus neutralization assays, the preclinical immunogenicity of the MERS-CoV vaccine was comprehensively examined when delivered subcutaneously by conventional needle injection or intracutaneously by dissolving MNAs.
The researchers discovered that MERS-S1 subunit vaccines delivered by MNA elicited robust and long-lasting antigen-specific antibody responses. Clinically translatable MNA SARS-CoV-2 subunit vaccines have been designed and produced inside 4 weeks of identification of the SARS-CoV-2 S1 sequence. These MNA-delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses, which have been seen beginning two weeks after immunization.
“Testing in patients would typically require at least a year and probably longer,” a coauthor mentioned in a press release. “Recently announced revisions to the normal processes suggest we may be able to advance this faster.”